The clinical safety and immuno-regulation effects of the nutritional selenium

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100051094

Enrollment

Unknown

Registered

2021-09-13

Start date

2021-10-01

Completion date

Unknown

Last updated

2022-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Short term supplementation:Oral supplemented with 2 capsules/day for 45 days

Long term supplementation:Oral supplemented with 2 capsules/day for 90 days

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Healthy volenteers aged in the range of 18-65 years old; 2. The volunteer is not supplemented with any health products especially selenium-riched ones within 2 months before attending this clinical trial.

Exclusion criteria

Exclusion criteria: 1. The volunteer who has long smoking history and/or excessive drinking; 2. The pregnant and allergic volunteers.

Design outcomes

Primary

Measure	Time frame
Aspartate Transaminase;Alanine transaminase;Urea nitrogen;Creatinine;Uric acid;Total bilirubin;Total proteins;Albumin;triglyceride;Total cholesterol;Creatine Kinase;Interleukin 1 beta;Total IgG;selenium level in blood;Gpx1;Gpx2;Gpx3;Gpx4;SEPP;TrxR1;blood routine examination;T lymphocytes;B lymphocytes;Natural killer cells;NKT cells;?d T cells;Granulocytes;	—

Countries

China

Contacts

Public ContactChen Tianfeng

Jinan University

tchentf@jnu.edu.cn+86 13826256681

Outcome results